Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
- About
HCW Biologics Inc(HCWB)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for HCWB
09/15/2026: HCWB (1-star) is currently NOT-A-BUY. Pass it for now.
HCW Biologics is a clinical-stage biotechnology company focused on developing immunotherapies to address age-related diseases through its proprietary TOBI technology platform. Its primary investment story hinges on the success of its lead candidate, HCW9218, and the long-term value of its discovery engine. While the company's innovation in senolytics is noteworthy, it remains pre-revenue and faces substantial risks related to clinical trial outcomes and intense competition from large, well-capitalized pharmaceutical entities. The stock is best suited for risk-tolerant, growth-oriented investors who monitor clinical trial progress and potential licensing developments. There is no dividend, and future performance remains highly dependent on successful execution of its complex research pipeline.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward exposure to biotechnology innovation, but growth is speculative and dependent on clinical trial success. |
| Momentum investor | Weak fit | Momentum investors typically seek stocks with strong positive price trends, which HCWB has not consistently demonstrated. |
| Value investor | Weak fit | As a pre-revenue company, traditional valuation metrics like P/E or EV/EBITDA are not applicable. |
| Dividend investor | Weak fit | The company does not pay a dividend and focuses entirely on research and capital preservation. |
| Low-risk investor | Weak fit | The extreme volatility and binary outcomes inherent in clinical-stage biotech make this unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are subject to extreme swings based on trial results and news flow. |
| Valuation risk | High | Valuations are highly speculative as there are no established earnings to support current market caps. |
| Competition risk (Pharma Giants) | High | The company competes with massive, well-capitalized firms that have dominant market positions. |
| Business quality | Medium | While the technology is novel, the business is currently limited by the lack of a commercial product. |
| Dividend income | Low / none | Investors should expect no dividend income for the foreseeable future. |
| Execution risk | High | The company's survival depends entirely on the successful execution of complex, expensive clinical trials. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -18.95% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.04M USD | Price to earnings Ratio - | 1Y Target Price 30 |
Price to earnings Ratio - | 1Y Target Price 30 | ||
Volume (30-day avg) 253.6K shares | Beta 2.38 | 52 Weeks Range 1.50 - 29.28 | Updated Date 09/15/2026 |
52 Weeks Range 1.50 - 29.28 | Updated Date 09/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -16.62 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Research & Licensing | Potential licensing fees for TOBI platform technology and eventual milestones/royalties from therapeutic candidates. | The company currently makes no revenue and relies on existing capital to fund its research projects. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9.86M | Price to Sales(TTM) 0.6 |
Enterprise Value 9.86M | Price to Sales(TTM) 0.6 | ||
Enterprise Value to Revenue 1.48 | Enterprise Value to EBITDA -3.63 | Shares Outstanding 1.84M | Shares Floating 1.65M |
Shares Outstanding 1.84M | Shares Floating 1.65M | ||
Percent Insiders 9.72 | Percent Institutions 9.03 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About HCW Biologics Inc
Exchange NASDAQ | Headquarters Miramar, FL, United States | ||
IPO Launch date 2021-07-20 | Founder, CEO, Director & Secretary Dr. Hing C. Wong Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 35 | Website https://www.hcwbiologics.com |
Full time employees 35 | Website https://www.hcwbiologics.com | ||
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.